C10orf111 Inhibitors
C10orf111 inhibitors encompass a variety of chemical compounds that target distinct aspects of the protein's function and regulation. Some inhibitors work by stopping the activation of C10orf111, achieved through the blocking of kinase activity that is crucial for its phosphorylation and subsequent activity. Others achieve inhibition by stabilizing the protein in its inactive form, either by targeting regulatory phosphatases that control its dephosphorylation or by binding to its regulatory domain, thereby preventing necessary conformational changes. Competitive inhibitors mimic the substrate of C10orf111, occupying its active site and thus impeding its enzymatic activity. Additionally, there are compounds that hinder the protein's maturation process by interfering with its proteolytic processing, which is essential for its functionality.
Further down the line of regulatory mechanisms, other inhibitors allosterically modulate C10orf111 to induce a structural alteration that reduces its interaction with essential co-factors, while some disrupt the protein's folding by inhibiting molecular chaperones, leading to its misfolding and subsequent degradation. Certain inhibitors exert their effects on the translational level by selectively binding to the mRNA of C10orf111, blocking its translation. There are also inhibitors that target post-translational modifications such as the acetylation of lysine residues, which are critical for the full activity of C10orf111. Others impede the proper cellular localization of C10orf111 by disrupting lipid rafts in the membrane or by blocking the interaction between C10orf111 and specific receptors it activates, thus inhibiting the downstream signaling pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that, by inhibiting mTORC1, can downregulate protein synthesis and potentially decrease the activity of proteins that are downstream of mTOR signaling, including C10orf111 if it is a downstream effector. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A kinase inhibitor that blocks the phosphorylation activities of various kinases. If C10orf111 function relies on phosphorylation by these kinases, staurosporine could reduce its activity through inhibition of phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor which would lead to the inhibition of the AKT signaling pathway. If C10orf111 activity is AKT-dependent, inhibition of PI3K would result in decreased function of C10orf111. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
A specific NUAK1 inhibitor that would inhibit the activity of kinases in the AMPK pathway, which if C10orf111 is a substrate of these kinases, would result in the functional inhibition of C10orf111. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An MEK inhibitor which prevents the activation of ERK1/2. If C10orf111 is an ERK1/2 dependent protein, then inhibition of MEK would result in decreased C10orf111 activity. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
A RAF kinase inhibitor that would prevent the activation of the MEK/ERK pathway. If C10orf111 operates downstream of this pathway, its activity would be decreased by GW5074. | ||||||
SL 0101-1 | 77307-50-7 | sc-204287 sc-204287A sc-204287B sc-204287C sc-204287D | 1 mg 10 mg 25 mg 50 mg 100 mg | $200.00 $353.00 $772.00 $1230.00 $2070.00 | 3 | |
An inhibitor of RSK (ribosomal S6 kinase), which is involved in the regulation of transcription and translation. If C10orf111 activity is RSK-dependent, inhibition by SL0101 would lead to reduced activity of C10orf111. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which affects transcription factors and other signaling proteins. If C10orf111 is part of the JNK signaling pathway, SP600125 would inhibit its activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor that affects the actin cytoskeleton and cell motility. If C10orf111 is involved in these cellular processes, inhibition of ROCK by Y-27632 could lead to the inhibition of C10orf111. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that if C10orf111 is p38 MAPK-dependent, would lead to a decrease in C10orf111 activity through the inhibition of this kinase. | ||||||